Genelux (NASDAQ:GNLX) Raised to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Genelux (NASDAQ:GNLX - Free Report) from a sell rating to a hold rating in a research note issued to investors on Saturday morning.

GNLX has been the subject of several other research reports. Benchmark lowered their price objective on shares of Genelux from $25.00 to $23.00 and set a "speculative buy" rating for the company in a research report on Thursday, May 8th. HC Wainwright reaffirmed a "buy" rating and set a $30.00 price objective on shares of Genelux in a report on Monday, March 31st. One equities research analyst has rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of "Buy" and a consensus target price of $17.75.

Genelux Price Performance

NASDAQ GNLX traded down $0.31 on Friday, hitting $3.07. The company had a trading volume of 155,188 shares, compared to its average volume of 172,869. Genelux has a 12-month low of $1.60 and a 12-month high of $5.89. The company has a market capitalization of $115.85 million, a PE ratio of -3.49 and a beta of -0.34. The company's fifty day moving average price is $2.78 and its 200-day moving average price is $3.15.

Genelux (NASDAQ:GNLX - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.24) by $0.03. On average, sell-side analysts anticipate that Genelux will post -0.88 EPS for the current year.

Institutional Investors Weigh In On Genelux

Large investors have recently made changes to their positions in the stock. LPL Financial LLC boosted its stake in shares of Genelux by 72.3% during the 4th quarter. LPL Financial LLC now owns 94,144 shares of the company's stock worth $222,000 after acquiring an additional 39,516 shares in the last quarter. Raymond James Financial Inc. purchased a new position in shares of Genelux in the 4th quarter worth $41,000. Marshall Wace LLP raised its position in Genelux by 51.4% in the fourth quarter. Marshall Wace LLP now owns 156,058 shares of the company's stock valued at $368,000 after purchasing an additional 52,958 shares during the period. Advisor Resource Council purchased a new position in Genelux in the first quarter valued at about $34,000. Finally, 5T Wealth LLC purchased a new position in Genelux in the first quarter valued at about $49,000. 37.33% of the stock is currently owned by hedge funds and other institutional investors.

About Genelux

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.